Rohto Pharmaceutical Co Ltd
TSE:4527
Rohto Pharmaceutical Co Ltd
Operating Income
Rohto Pharmaceutical Co Ltd
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Rohto Pharmaceutical Co Ltd
TSE:4527
|
Operating Income
¥40.6B
|
CAGR 3-Years
25%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
Shiseido Co Ltd
TSE:4911
|
Operating Income
¥19.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-9%
|
|
Pola Orbis Holdings Inc
TSE:4927
|
Operating Income
¥16.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
0%
|
|
Kao Corp
TSE:4452
|
Operating Income
¥86.6B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-4%
|
|
F
|
Fancl Corp
TSE:4921
|
Operating Income
¥11.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
14%
|
Kobayashi Pharmaceutical Co Ltd
TSE:4967
|
Operating Income
¥25.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
4%
|
See Also
What is Rohto Pharmaceutical Co Ltd's Operating Income?
Operating Income
40.6B
JPY
Based on the financial report for Dec 31, 2023, Rohto Pharmaceutical Co Ltd's Operating Income amounts to 40.6B JPY.
What is Rohto Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
9%
Over the last year, the Operating Income growth was 18%. The average annual Operating Income growth rates for Rohto Pharmaceutical Co Ltd have been 25% over the past three years , 14% over the past five years , and 9% over the past ten years .